论文部分内容阅读
目的:观察氯吡格雷对非ST段抬高型急性冠状动脉综合征患者的治疗作用及干预治疗8周内心血管事件发生率的影响。方法:80例非ST段抬高型急性冠状动脉综合征患者随机分为对照组(40例)和干预组(40例),对照组给予常规治疗,干预组在常规治疗基础上给予氯吡格雷负荷量300 mg后,75 mg/次,1次/d,连用8周,评价并比较治疗8周时2组临床疗效及干预治疗8周内心血管事件的发生率。结果:治疗8周时,干预组临床疗效高于对照组,8周内心血管事件发生率低于对照组,差异有统计学意义(P<0.05)。结论:氯吡格雷可提高非ST段抬高型急性冠状动脉综合征患者临床疗效,降低住院期间病死率和近期心血管事件发生率。
Objective: To observe the therapeutic effect of clopidogrel on patients with non-ST segment elevation acute coronary syndrome and the effect of intervention on the incidence of cardiovascular events within 8 weeks. Methods: Eighty non-ST-elevation acute coronary syndrome patients were randomly divided into control group (40 cases) and intervention group (40 cases). The control group was given routine treatment. The intervention group was given clopidogrel After loading 300 mg, 75 mg once daily for 8 weeks, the clinical curative effect and the incidence of cardiovascular events in 8 weeks after treatment were evaluated and compared. Results: At 8 weeks of treatment, the clinical efficacy of the intervention group was higher than that of the control group. The incidence of cardiovascular events within 8 weeks was lower than that of the control group (P <0.05). Conclusion: Clopidogrel can improve the clinical efficacy of non ST-segment elevation acute coronary syndrome patients and reduce the mortality and recent cardiovascular events during hospitalization.